Women with IIH and telemetric ICP monitors (n = 15) were treated with exenatide (n = 7) or placebo (n = 8) for 12 weeks
Supplementary Information 13073_2026_1630_MOESM1_ESM.docx (download DOCX Supplementary Material 1: contains supplementary methods, supplementary Tables 15, pharmacogenetic cohort details and study plan
Melissa is great at what she does
Genes Dev 2012
Conclusion: SIBO Can Be Treatedand PreventedWith the Right Strategy SIBO is a complex but manageable condition when addressed with a root-cause, functional medicine approach
Overall, 140 participants (32.1%) reported lifetime use of semaglutide, tirzepatide, dulaglutide, liraglutide, or exenatide, used for either diabetes management or weight loss, while 96 (22%) reported current use